The challenge of achieving target drug concentrations in clinical trials: Experience from the symphony study

Transplantation

Volumn 87, Issue 9, 2009, Pages 1360-1366

  Ekberg, Henrik ^a,f   Mamelok, Richard D ^b   Pearson, Thomas C ^c   Vincenti, Flavio ^d   Tedesco Silva, Hélio ^e   Daloze, Pierre ^f  

^a LUND UNIVERSITY   (Sweden)

^b Mamelok Consulting   (United States)

^c EMORY UNIVERSITY   (United States)

^d UCSF Medical Center at Parnassus   (United States)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f NOTRE DAME HOSPITAL   (Canada)

Author keywords

Calcinuerin inhibitors; Mycophenolate mofetil; Target drug concentration

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG TARGETING; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; TARGET CELL DESTRUCTION;

ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; CADAVER; CLINICAL TRIALS AS TOPIC; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; RESEARCH DESIGN; SIROLIMUS; TACROLIMUS; TISSUE DONORS;

EID: 67649595499     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181a23cb2     Document Type: Article

References (11)

1. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
2. Ekberg H, Persson NH, Källen R, et al. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation. Scand J Immunol 2003; 58: 670.
3. Kuypers DR, Evenepoel P, Maes B, et al. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. Clin Transplant 2003; 17: 234.
4. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR study. Am J Transplant 2006; 6: 1.
5. Grinyo JM, Campistol JM, Paul J, et al. Pilot randomized study of early tacrolimus withdrawal from a regimen with sirolimus plus tacrolimus in kidney transplantation. Am J Transplant 2004; 4: 1308.
6. van Hooff JP, Squifflet JP, Wlodarczyk Z, et al. A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients. Transplantation 2003; 75: 1934.
7. Gaston R, Shah T, Bloom R, et al. Opticept trial: Interim results of 12-month efficacy and safety of monitored mycophenolate mofetil (MMF) in combination with CNI in renal transplantation. ATC Congress, San Francisco, CA, 2007, abstract number 1163.
8. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixeddose concentration-controlled trial. Transplantation 2008; 86: 1043.
9. Le Meur Y, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 2007; 7: 2496.
10. Meier-Kriesche H-U, Halloran PF, Vanrenterghem Y, et al. Early immunosuppression exposure and incidence of acute rejection and renal function progression: Evidence from the Symphony Study. Transpl Int2007; 20: 19 (abstract 065).
11. van Gelder T, Le Meur Y, Shaw LM, et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 2006; 28: 145.